Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster weight-loss and diabetes drugs in the U.S. hold back its sales.

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, cut its annual sales forecast on Wednesday, citing a decline in its US market share. Novo Nordisk's shares tumbled last month after Eli Lilly announced a successful clinical trial of diabetes and obesity treatment orforglipron.